1. Home
  2. SVRA vs DBVT Comparison

SVRA vs DBVT Comparison

Compare SVRA & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVRA
  • DBVT
  • Stock Information
  • Founded
  • SVRA 2007
  • DBVT 2002
  • Country
  • SVRA United States
  • DBVT France
  • Employees
  • SVRA N/A
  • DBVT N/A
  • Industry
  • SVRA Biotechnology: Pharmaceutical Preparations
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SVRA Health Care
  • DBVT Health Care
  • Exchange
  • SVRA Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • SVRA 527.2M
  • DBVT 434.7M
  • IPO Year
  • SVRA N/A
  • DBVT N/A
  • Fundamental
  • Price
  • SVRA $3.60
  • DBVT $15.92
  • Analyst Decision
  • SVRA Buy
  • DBVT Buy
  • Analyst Count
  • SVRA 8
  • DBVT 4
  • Target Price
  • SVRA $6.63
  • DBVT $14.81
  • AVG Volume (30 Days)
  • SVRA 1.1M
  • DBVT 143.6K
  • Earning Date
  • SVRA 11-11-2025
  • DBVT 11-05-2025
  • Dividend Yield
  • SVRA N/A
  • DBVT N/A
  • EPS Growth
  • SVRA N/A
  • DBVT N/A
  • EPS
  • SVRA N/A
  • DBVT N/A
  • Revenue
  • SVRA N/A
  • DBVT $3,800,000.00
  • Revenue This Year
  • SVRA N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • SVRA N/A
  • DBVT $1,044.34
  • P/E Ratio
  • SVRA N/A
  • DBVT N/A
  • Revenue Growth
  • SVRA N/A
  • DBVT N/A
  • 52 Week Low
  • SVRA $1.89
  • DBVT $2.21
  • 52 Week High
  • SVRA $4.30
  • DBVT $16.98
  • Technical
  • Relative Strength Index (RSI)
  • SVRA 61.30
  • DBVT 72.21
  • Support Level
  • SVRA $3.35
  • DBVT $14.63
  • Resistance Level
  • SVRA $3.53
  • DBVT $16.90
  • Average True Range (ATR)
  • SVRA 0.13
  • DBVT 1.26
  • MACD
  • SVRA -0.03
  • DBVT 0.46
  • Stochastic Oscillator
  • SVRA 72.31
  • DBVT 83.03

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: